A-PQ 30®, primaquine 30 mg

  • Product

    A-PQ 30, primaquine 30 mg, tablets with cross breakline

  • Authorisation

    Unlicensed medicine

  • Active ingredient

    Primaquine 30 mg (as primaquine diphosphate)

  • Indication

    Malaria tertiana due to P. vivax or P. ovale infections; Moderate to severe Pneumocystis jiroveci– infections in combination with clindamycine

  • Storage condition

    Below 25 °C

A-PQ 30 contains the active substance primaquine, which is an 8-aminoquinoline derivative that suppresses the malaria parasites in the liver stage. It is used for treatment of relapses (radical cure) of malaria tertiana as a result of infections with Plasmodium vivax or Plasmodium ovale.

A-PQ 30 is also prescribed for the treatment of opportunistic Pneumocystis jiroveci-infections.

As the tablet can be divided in four, each multiple of 7.5 mg can be administered.

Legal status

A-PQ 30 is an unlicensed medicine in the Netherlands. The Dutch Health Care Inspectorate (IGJ) has given permission for the supply.

A-PQ 30 is supplied on named patient basis. An order signed by the pharmacist and a physician’s statement from the prescribing physician are required with every order.

Availability for Pharmacies

Pharmacies outside the Netherlands that would like to know more about the availability of this product are welcome to contact us via our contact form.

If you have ordered A-PQ 30 with us before, please use the order form to place a new order. Click on ‘Products’ in the menu to find our current order form.

Distribution activities

Since August 2018 the distribution activities of ARTECEF BV have been transferred to sister company Ace Pharmaceuticals BV.